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ABSTRACT 
The present study deals with the formulation and evaluation of transdermal patches of Glibenclamide towards enhance its 
permeation through the skin and maintain the plasma level concentration. Transdermal patches were prepared by using polymers like 
Chitosan, HPMC 15cps and EC 20cpsat various concentrations by solvent casting technique employing dibutyl phthalate as 
plasticizer and iso-propylmyristate as permeation enhancer. The transdermal patches were evaluated for their physico-chemical 
properties and in-vitro drug release. The transdermal patches were found to be transparent and smooth in texture. Among the 
formulations studied, at the end of 12th hour, the minimum and maximum in-vitro drug release was observed for the formulations 
F12 and F4 i.e. 80.012 ± 2.012 % and 98.365±3.012% respectively. The mechanism of drug release was found to be Non-Fickian 
diffusion controlled. FT-IR studies revealed the integrity of the drug in the formulations. 
Keywords: Transdermal Patches, Glibenclamide, Chitosan, HPMC 15cps, EC 20 cps, in-vitro diffusion studies.  
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INTRODUCTION 
Transdermal drug delivery system has been in existence 
for a long time. In the past, the most commonly applied 
systems were topically applied creams and ointments for 
dermatological disorders the occurrence of systemic 
side-effects with some of these formulations is indicative 
of absorption through the skin
1
. A number of drugs have 
been applied to the skin for systemic treatment. In a 
broad sense, the term transdermal delivery system 
includes all topically administered drug formulations 
intended to deliver the active ingredient into the general 
circulation
2
.  
Transdermal therapeutic systems have been designed to 
provide controlled continuous delivery of drugs via the 
skin to the systemic circulation
3-4
. Moreover, it over 
comes various side effects like painful delivery of the 
drugs and the first pass metabolism of the drug occurred 
by other means of drug delivery systems
5
.     
Glibenclamide and other NSAIDs the mechanism of 
release was diffusion mediated. The developed 
transdermal patches increase the efficacy of 
Glibenclamide for the therapy of arthritis and other 
painful muscular conditions
6-8
. Conventional systems of 
medication which require multi dose therapy have 
numerous problems and most recently, there is an 
increasing recognition that the skin can serve as the port 
provide continuous transdermal drug infusion into the 
systemic circulation
9-12
. Transdermal therapeutic 
systems are defined as self-contained, discrete dosage 
forms when applied to the intact skin deliver the drug 
through the skin at controlled rate to the systemic 
circulation
15-19
. So, in present study formulated, 
evaluated and in-vitro drug release studies of 
Glibenclamide. 
MATERIAL AND METHODS 
Glibenclamide hydrochloride was received as a gift 
samples from Cadila Pharmaceutical, Ahmedabad and 
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polymers are obtained from. Other chemicals used in the 
study were of analytical grade. Double-distilled water 
was used throughout the study. 
Preparation of Transdermal Patches 
The transdermal patches of Glibenclamide were 
prepared using combination of three polymers i.e. 
(Chitosan, HPMC, EC) (Table 1) in a suitable solvent 
system by solvent casting technique.  Calculated amount 
of Glibenclamide was dissolved in methanol and was 
dispersed in polymeric solution. Dibutyl phthalate is 
used as plasticizer (30% weight of polymer) and 
Isopropyl myristate served as permeation enhancer (5% 
weight of polymer) were added and stirred to form 
uniform mixture. The resultant mixture was poured into 
petri dish having glass bangle (diameter 4.5 cm) lined 
with aluminum foil as a backing membrane.  The 
prepared patches were allowed to dry at room 
temperature for 24 hrs. For complete drying, the moulds 
were kept in a hot air oven maintained at 45 ± 1ºC for 
another 4 hours. After complete drying, the patches were 
removed and stored in desiccators until used. The 
patches were smooth, flexible and could be cut to any 
desired size and shape
20-26
. 
Evaluation of transdermal patches 
The transdermal patches were evaluated for the 
following parameters. 
Physical Appearance 
All the prepared patches were visually inspected for 
color, clarity, flexibility and smoothness. 
Thickness Uniformity  
The thickness of the formulated film was measured at 3 
different points using a mitutoya thickness gage 7301 
made in Japan thickness of three reading was calculated. 
Average thickness was determined. 
Folding Endurance  
The folding endurance was determined to determine 
flexibility of film. The flexibility of the film is needed to 
handle the film easily and for comfortable, secured 
application of film on the wound. It was determined by 
repeatedly folding one film at same place till it breaks or 
folded up to 300 times manually. The number of times 
of film could be folded at the same place without 
breaking give the value of folding endurance. 
Water Absorption Capacity  
It is of utmost importance, if they are used for biological 
applications and wound healing. It is used to measure 
the capacity of film to absorb wound exudates. The 
initial weight of 1inch of dry film was noted. Then this 
film was placed in 15ml. of distilled water taken in Petri 
plate. The weight of the film was noted periodically at 
first hour, second hour, third hour and 24th hour. Every 
time after noting the weight, the film was placed in fresh 
water. Water absorption capacity of the film was 
calculated using a formula: 
% Moisture Absorption = 
            –              
              
      
Percentage Moisture Loss 
The films were weighed accurately and kept in a 
desiccators containing anhydrous calcium chloride. 
After 3 days, the films were taken out and weighed. The 
moisture loss was calculated using the formula: 
% Moisture loss = 
              –              
              
      
Water Vapor Transmission Rate  
Glass vials of 5 ml capacity were washed thoroughly and 
dried to a constant weight in an oven. About 1 g of fused 
calcium chloride was taken in the vials and the polymer 
films of2.25 cm2 were fixed over the brim with the help 
of an adhesive tape. Then the vials were weighed and 
stored in a humidity chamber of 80-90 % RH condition 
for a period of 24 h. The vials were removed and 
weighed at 24 h time intervals to note down the weight 
gain.  
Transmission rate =
            –              
           
      
Tensile strength 
Tensile strength of the film was determined with 
Universal strength testing machine (JUSTY, Tensile 
Testing Machine, JTM 50 digital). The sensitivity of the 
machine was 1 g. It consisted of two load cell grips. The 
lower one was fixed and upper one was movable. The 
test film of size (10 × 10 mm
2
) was fixed between these 
cell grips and force was gradually applied till the film 
broke. The tensile strength of the film was taken directly 
from the dial reading in kg. Tensile strength is expressed 
as follows: 
Tensile Strength =
                     
                  
 
Drug content 
An accurately cut patch of 1cm
2
 area was taken and 
added to a beaker containing 1 ml phosphate buffer 
solution of pH 7.4 The beaker was kept 24 hours with 
occasion shaking. The sample was analyzed drug 
content using UV spectrophotometer 248nm.This study 
was performed for 3 times for a single patch. 
In vitro Drug Release Studies 
The in vitro evaluation was carried out in the modified 
Franz diffusion cell. This consists of an upper donor 
compartment and the lower receptor compartment, 
surrounded by water jacket for circulation of water to 
maintain the temperature inside at 32±1
0
C.The 
uniformity of solution in the receptor phase was 
maintained by stirring at high speed of 100 rpm 
(approximately) using a tiny magnetic bead the volume 
of receptor compartment was maintained at 60 ml and 
the diffusion surface are of 0.785 cm
2
. The receptor 
compartment was provided with the sampling port on 
one side, to withdraw sample at the predetermined time 
intervals for estimation of drug content by UV 
spectrophotometer.
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Table 1: Composition of Glibenclamide Transdermal Patches 
Formulation 
Code 
Polymers Plasticizer 
(30 % w/v) (DBT) 
Permeation Enhancer 
(30% w/v) IPM 
Chitosan HPMC EC 
F1 5 - - 30 5 
F2 - 5 - 30 5 
F3 2 3 - 30 5 
F4 3 2 - 30 5 
F5 3.5 1 0.5 30 5 
F6 3 1.5 0.5 30 5 
F7 2.5 1.5 1 30 5 
F8 2.5 2.5 0 30 5 
F9 3 1 1 30 5 
F10 2 2 1 30 5 
F11 2.5 2.5 0 30 5 
F12 1.5 3.5 0 30 5 
 
Experimental conditions 
The receptor medium was phosphate buffer solution of 
pH 7.4, temperature of the receptor medium was 
maintained at 37 ± 2
0
 C throughout the experiment using 
water jacket. The donor compartment was in contact 
with ambient condition of atmosphere. 
RESULT AND DISCUSSION 
In the present study, glibenclamide transdermal patches 
were prepared by solvent casting method. Polymers 
used for this study Chitosan, HPMC, EC employing 
aluminum foil as the backing membrane, Dibutyl 
phthalate used as plasticizer and Isopropyl myristate as 
permeation enhancer. 
Thickness 
The transdermal patches were transparent, smooth, 
uniform and flexible. Thicknesses of transdermal 
patches were found to be in the range of 0.02266 ± 
0.0015 mm to 0.03533 ± 0.0025 mm (Table 2). The low 
standard deviation values in the film thickness ensure 
uniformity of the patches prepared by solvent casting 
technique. The weights of formulations were found to be 
in the range of 0.1130 ± 0.0040 gm to 0.1736 ± 0.0015 
gm. This indicated that there is no significant weight 
variation in all formulations and are as shown in Table 
2.
 
Table 2: Physical Characterization of GLIBENCLAMIDE Transdermal Patches 
Formulation 
Code 
Thickness (mm)
*
 
Mean ±SD 
Weight Variation (g)
*
 
Mean ±SD 
Folding Endurance
* 
Mean ±SD 
Drug Content (%)
* 
Mean±SD 
F1 0.025±0.0030 0.1255±0.0052 146.3333±4.5092 97.4± .45 
F2 0.022±0.0030 0.1455±0.0025 163.6666±2.3025 97.98± .42 
F3 0.013±0.0015 0.1256±0.0041 169.0000±1.2563 99± .255 
F4 0.035±0.0025 0.1366±0.0025 155.6666±3.5263 97.37± .48 
F5 0.020±0.0032 0.1478±0.0063 136.3333±1.4415 96.00± .48 
F6 0.032±0.0015 0.1585±0.0048 152.0000±2.3632 97.52±1.4 
F7 0.021±0.0010 0.1263±0.0036 152.6666±5.3652 97.99± .79 
F8 0.015±0.0020 0.2665±0.0074 136.3333±4.2635 98.82± .39 
F9 0.025±0.0032 0.2556±0.0045 140.6666±4.3652 97.9± .79 
F10 0.026±0.0020 0.2636±0.0012 150.3333±4.5665 98.82± .39 
F11 0.04±0.0032 0.4553±0.0036 146.6666±3.2365 97.9± .70 
F12 0.04±0.0032 0.2663±0.0063 142.0000±1.2556 98.5±.25 
* Average of three determination 
 
Folding Endurance 
In order to evaluate the flexibility, the films were 
subjected to folding endurance studies. The values in the 
range of 138 to 176 were observed in all batches. This 
revealed that the prepared films were having capability 
to withstand the mechanical pressure along with good 
flexibility. The formulation F6 was found to have lowest 
folding endurance, whereas formulation F4 was found to 
have highest folding endurance. The folding endurance 
results were shown in Table 2. 
Percentage Moisture Uptake and Loss 
Among the formulations, F1 showed maximum moisture 
uptake i.e. 3.4533 ± 0.2318 % and F4 showed minimum 
moisture uptake i.e. 1.3433 ± 0.1457%. The percentage 
moisture uptake results are as shown in Table 2. Among 
the formulations, F10 showed maximum moisture loss 
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i.e. 4.3300 ± 0.0360 % and F1 showed minimum 
moisture loss i.e. 1.5150 ± 0.2700%. The percentage 
moisture loss results are as shown in Table 2. 
Tensile strength 
The tensile strength was determined by using tensile 
strength tester (Test techno consultant, Vadodara) 
having the capacity of 10 kg. The results are as shown in 
Table 2. It was found that the formulation F4 and F1 
shown maximum (0.6130 ± 0.0010 kg/cm2) and 
minimum (0.3250 ± 0.0036 kg/cm2) tensile strength 
respectively among all the formulations. 
Bursting strength 
The bursting strength was determined by using bursting 
strength tester (Test Techno Consultant, Vadodara) 
having the capacity of 10 kg. From results are as shown 
in Table 2, it is found that the formulation F4 and F8 
shown maximum (2.9 kg/cm2) and minimum (2.2 
kg/cm2) bursting strength respectively among all the 
formulations.  
Drug content uniformity 
The drug content uniformity of all the formulations was 
determined. The results of the drug content in all the 
formulations were found to be in the range of 96.5833 ± 
1.5593 % to 98.4366 ± 0.9281 % and are as shown in 
Table 2.  
In-vitro drug release 
The results of the Table 3 indicated the cumulative 
percentage drug release of various formulations. The 
cumulative percentage of drug released in 12 h was 
found to be minimum and maximum for the 
formulations F4 and F10 i.e. 81.023 ± 3.013 % and 
98.564 ±3.005%. The in-vitro release data obtained from 
different formulations of Glibenclamide was plotted for 
cumulative percent drug release versus time. First order 
plots are plotted by taking log cumulative percent drug 
remaining versus time. (Figure 1) To ascertain the drug 
release mechanism, the formulations were plotted for 
Higuchi diffusion plots (Figure 2) by taking cumulative 
percent drug release versus square root of time. The 
plots were found to be fairly linear and the regression 
coefficient values were nearer to 1 in all the cases. So it 
confirmed that the drug release mechanism was 
diffusion mechanism. The formulations were also treated 
to Peppa’s plot by taking log percent release versus log 
time (Figure 3). The plots are found to be fairly linear 
and the regression values are nearer to 1. The values of 
slope of peppa’s suggest that thedrug was released by 
Non-Fickian diffusion control (Anomalous diffusion) 
without any swelling. 
 
  
                                       1(A)                                                                      1(B) 
 
1(C) 
Figure 1 Percentage Drug Release v/s Time (F1 to F12) 
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Figure 2 Percentage Drug Release v/s Time (Higuchi 
Diffusion Plots) 
 
Figure 3 Percentage Drug Release v/s Time (Peppa’s 
Plot) 
 
Table 3: In-vitro Drug Release Studies 
Time CUMULATIVE PERCENT RELEASED 
F1 F2 F3 F4 F5 F6 
0 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 
1 4.535±1.042 4.953±1.025 7.025±1.008 8.025±1.025 7.058±3.256 6.456±3.965 
2 11.485±2.365 10.258±1.358 11.852±2.058 18.540±2.004 11.442±2.023 15.665±3.258 
3 19.575±1.358 18.258±1.023 17.458±2.365 24.557±2.014 32.225±3.025 24.369±2.122 
4 27.578±1.025 22.145±2.032 24.258±2.352 33.254±1.250 25.189±2.258 21.258±1.852 
5 32.320±2.025 25.014±1.470 33.591±3.025 23.65±3.034 36.021±2.785 22.568±2.596 
6 42.023±1.235 36.256±2.365 43.258±3.221 48.369±2.325 50.258±2.358 36.223±0.230 
7 51.236±2.369 46.325±2.322 54.203±3.025 55.025±3.780 59.365±3.025 60.254±3.258 
8 59.365±3.252 55.362±2.014 56.236±3.666 58.885±2.258 59.263±2.258 56.254±2.014 
9 66.258±2.365 63.201±3.025 72.025±2.367 76.365±3.247 68.325±2.015 63.021±2.014 
10 74.365±3.202 72.365±2.012 70.367±1.025 73.036±2.025 74.012±2.012 72.032±3.012 
11 75.125±3.012 76.212±2.201 77.012±3.036 75.012±3.312 74.014±2.012 76.012±3.063 
12 86.015±1.005 83.012±2.012 95.850±1.025 98.365±3.012 90.254±1.025 96.025±1.022 
 
Table 4: In-vitro Drug Release Studies 
Time CUMULATIVE PERCENT RELEASED 
F7 F8 F9 F10 F11 F12 
0 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 
1 8.025±1.025 6.456±3.965 7.025±1.008 4.535±1.042 7.058±3.256 4.953±1.025 
2 18.540±2.004 15.665±3.258 11.852±2.058 11.485±2.365 11.442±2.023 10.258±1.358 
3 24.557±2.014 24.369±2.122 17.458±2.365 19.575±1.358 32.225±3.025 18.258±1.023 
4 33.254±1.250 21.258±1.852 24.258±2.352 27.578±1.025 25.189±2.258 22.145±2.032 
5 23.65±3.034 22.568±2.596 33.591±3.025 32.320±2.025 36.021±2.785 25.014±1.470 
6 48.369±2.325 36.223±0.230 43.258±3.221 42.023±1.235 50.258±2.358 36.256±2.365 
7 55.025±3.780 60.254±3.258 54.203±3.025 51.236±2.369 59.365±3.025 46.325±2.322 
8 58.885±2.258 56.254±2.014 56.236±3.666 59.365±3.252 59.263±2.258 55.362±2.014 
9 76.365±3.247 63.021±2.014 72.025±2.367 66.258±2.365 68.325±2.015 63.201±3.025 
10 73.036±2.025 72.032±3.012 70.367±1.025 74.365±3.202 74.012±2.012 72.365±2.012 
11 75.012±3.312 76.012±3.063 77.012±3.036 75.125±3.012 74.014±2.012 76.212±2.201 
12 97.365±3.012 96.025±1.022 95.850±1.025 86.015±1.005 90.254±1.025 80.012±2.012 
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CONCLUSION 
The patches of Glibenclamide prepared using the 
polymers HPMC 15cps, Chitosan and EC were of 
smooth surface, good appearance, uniform thickness and 
weight variation with minimum standard deviation. The 
ratio of hydrophilic and hydrophobic polymeric film 
formers affected the mechanical properties, percentage 
moisture uptake and rate of drug release. With 
increasing levels of EC in the formulations the release 
rates were lowered. It can be concluded that 
Glibenclamide can be delivered by transdermal route in 
a controlled manner into the systemic circulation to 
maintain therapeutic drug levels for prolonged periods. 
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